Taselisib (GDC-0032), a Potent  -Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations

Baselga, José; Chung, Christine H.; Ganly, Ian; Gupta, Gaorav; Higginson, Daniel S.; Krigsfeld, Gabriel; Lee, Nancy Y.; Morris, Luc; Morse, Natasha; Powell, Simon N.; Scaltriti, Maurizio; Shiao, Stephan L.; Zumsteg, Zachary S.

Taselisib (GDC-0032), a Potent -Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations

Authors: José Baselga
Christine H. Chung
Ian Ganly
Gaorav Gupta
Daniel S. Higginson
Gabriel Krigsfeld
Nancy Y. Lee
Luc Morris
Natasha Morse
Simon N. Powell
Maurizio Scaltriti
Stephan L. Shiao
Zachary S. Zumsteg
Publication date: 1 January 2016
Publisher
Doi

Abstract

Activating PIK3CA genomic alterations are frequent in head and neck squamous cell carcinoma (HNSCC), and there is an association between phosphoinositide 3-kinase (PI3K) signaling and radioresistance. Hence, we investigated the therapeutic efficacy of inhibiting PI3K with GDC-0032, a PI3K inhibitor with potent activity against p110α, in combination with radiation in HNSCC

Similar works

Full text

Open in the Core reader

Download PDF

Available Versions

Carolina Digital Repository

cdr.lib.unc.edu:f1881r89k

Last time updated on 23/04/2020